The inhibition of Janus kinase II (JAK2) impairs STAT3 activation in PAECs from PAH patients, reducing growth factors, decreasing proliferation and migration rates and promoting cell survival [36]. The gene discussed is STAT3; the disease is pulmonary arterial hypertension.